Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACNS 0331 in newly diagnosed standard-risk medulloblastoma
NL-OMON35496Phase 3Active, not recruiting
- Sponsor
- SKion
- Start
- Dec 2011
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vincristine, lomustine, cisplatin and cyclophosphamide in medulloblastoma (4 arms), sponsored by SKion. Primary endpoints: Event-free survival and Overall survival. Started Dec 2011; status: active, not recruiting.
02
Drugs
vincristinelomustinecisplatincyclophosphamide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON35496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35496.